Animal models for SARS-CoV-2: vaccines and immune enhancement [Added supplement: Sex as a biological variable Supplement]

  • Funded by Canadian Institutes of Health Research (CIHR)
  • Total publications:0 publications

Grant number: 170349, 171489

Grant search

Key facts

  • Disease

    COVID-19
  • Start & end year

    2020
    2022
  • Known Financial Commitments (USD)

    $794,842.68
  • Funder

    Canadian Institutes of Health Research (CIHR)
  • Principal Investigator

    Darryl Falzarano
  • Research Location

    Canada
  • Lead Research Institution

    University of Saskatchewan
  • Research Priority Alignment

    N/A
  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Disease models

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

In December 2019 a novel coronavirus (CoV) was identified as the cause of pneumonia in a cluster of patients in Wuhan, China. This virus is related to severe acute respiratory syndrome (SARS)-CoV and has been named SARS-CoV-2. In less than two months, there have been over 69,000 cases and over 1600 deaths. Quarantine measures have been imposed on entire cities in China in an attempt to control spread. Cases of SARS-CoV-2 have been identified in 28 other countries and there is concern that this could lead to global pandemic. Here we propose to identify what common lab and agricultural animals may be infected with SARS-CoV-2. This addresses two important questions. What animals can be infected and may pose a risk (or are at risk) and can these animals be used to models. Animal model allow us to understand how the virus causes disease, whether vaccines can be developed that protect from disease and how might the virus be transmitted. These are critical questions that need to be addressed when a new pathogen emerges. In addition, there is some concern that less than optimal vaccines or previous exposure to related pathogens could exaserbate disease - this is a somewhat unique phenomenom that was observed with SARS-CoV vaccines. We plan to investigate whether these animal models can be used to test for this, to ensure that vaccines are safe prior to testing in human clinical trials